The Latest Breaking News from Biogen

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.

Eisai Co. unveiled much-anticipated findings on its experimental Alzheimer’s drug, providing tinder for the hot debate over whether its modest efficacy is worth potential risks that include serious brain bleeding.

Despite signs of inflation cooling in the United States, the IMF is not expecting the global economic picture to improve anytime soon. However, the cooling inflation might induce the Fed to ease the pace of rate hikes. As economic uncertainties remain, we think fundamentally solid stocks McDonald’s (MCD) and Biogen…

Biogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to recover from its failed launch of the Alzheimer’s treatment Aduhelm

Upgrades

A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 12 strange trades.

TAMPA, Fla. -- At 53, Michele Hall was at the height of her legal career. She’d just sent her three kids to college. She had decades ahead with her husband Doug — after nearly 30 years of marriage, the couple looked forward to celebrating 30 more.

Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Upgrades